Cargando…

Geographic-Level Association of Contemporary Changes in Localized and Metastatic Prostate Cancer Incidence in the Era of Decreasing PSA Screening

Decreased prostate-specific antigen screening since 2008 has generated much concern, including report of recent increase in metastatic prostate cancer incidence among older men. Although increased metastatic disease was temporally proceeded by decreased screening and decreased localized prostate can...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Daniel X., Makarov, Danil V., Gross, Cary P., Yu, James B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7003204/ https://www.ncbi.nlm.nih.gov/pubmed/32003227 http://dx.doi.org/10.1177/1073274820902267

Ejemplares similares

Metastatic prostate cancer in the modern era of PSA screening
por: Fontenot, Philip A., et al.
Publicado: (2017)

Lycopene, Tomato Products, and Prostate Cancer Incidence: A Review and Reassessment in the PSA Screening Era
por: Wei, Melissa Y., et al.
Publicado: (2012)

A qualitative study to understand guideline-discordant use of imaging to stage incident prostate cancer
por: Makarov, Danil V., et al.
Publicado: (2016)

Incidence trends of prostate cancer in East Anglia, before and during the era of PSA diagnostic testing
por: Pashayan, N, et al.
Publicado: (2006)

Multiparametric MRI in the PSA Screening Era
por: George, Arvin K., et al.
Publicado: (2014)

Using a Recurrent Neural Network To Inform the Use of Prostate-specific Antigen (PSA) and PSA Density for Dynamic Monitoring of the Risk of Prostate Cancer Progression on Active Surveillance
por: Sushentsev, Nikita, et al.
Publicado: (2023)

Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer
por: Tomioka, Atsushi, et al.
Publicado: (2014)

Impact of COVID‐19 on the incidence of localized and metastatic prostate cancer among White and Black Veterans
por: Lee, Kyung Min, et al.
Publicado: (2022)

Incidence of Histological Prostatitis and Its Correlation with PSA Density
por: Piovesan, Affonso Celso, et al.
Publicado: (2009)

Mobile PSA: A Novel Telehealth Tool for Prostate Cancer Follow-Up
por: Bergroth, Robin, et al.
Publicado: (2021)

PSA Decrease with Fulvestrant Acetate in a Hormone-Resistant Metastatic Prostate Cancer Patient: A Case Report
por: Gasent Blesa, Joan Manel, et al.
Publicado: (2009)

Contemporary outcomes following robotic prostatectomy for locally advanced and metastatic prostate cancer
por: McCormick, Barrett Z., et al.
Publicado: (2021)

Metastatic Prostate Cancer Diagnosed by Bone Marrow Aspiration in an Elderly Man Not Undergoing PSA Screening
por: Alam, Ridwan, et al.
Publicado: (2017)

Synthetic CRISPR/dCas9-KRAB system driven by specific PSA promoter suppresses malignant biological behavior of prostate cancer cells through negative feedback inhibition of PSA expression
por: Yang, Yi, et al.
Publicado: (2023)

Early Experience with MRI-ultrasound Fusion-guided Prostate Biopsy in Japanese Men with Elevated PSA Levels
por: Tamada, Tsutomu, et al.
Publicado: (2019)

Urinary PSA and Serum PSA for Aggressive Prostate Cancer Detection
por: Höti, Naseruddin, et al.
Publicado: (2023)

Multiple Docetaxel Retreatments Without Prednisone for Metastatic Castration-Resistant Prostate Cancer in the Docetaxel-Only Era: Effects on PSA Kinetics and Survival
por: Maj-Hes, Agnieszka, et al.
Publicado: (2021)

Physician Consultations, Prostate Cancer Knowledge, and PSA Screening of African American Men in the Era of Shared Decision-Making
por: Woods-Burnham, Leanne, et al.
Publicado: (2018)

Case report: Incidental metastatic prostate cancer with undetectable PSA in pelvic lymphadenectomy
por: McLeay, Matthew T., et al.
Publicado: (2018)

Clinicopathological characteristics of localized prostate cancer in younger men aged ≤ 50 years treated with radical prostatectomy in the PSA era: A systematic review and meta‐analysis
por: Zheng, Yu, et al.
Publicado: (2020)

Assessment of factors associated with PSA level in prostate cancer cases and controls from three geographical regions
por: Karunasinghe, Nishi, et al.
Publicado: (2022)

Lenalidomide decreased the PSA level for castration‐resistant prostate cancer: a case report
por: Shimokihara, Kota, et al.
Publicado: (2018)

Decreased fucosylated PSA as a urinary marker for high Gleason score prostate cancer
por: Fujita, Kazutoshi, et al.
Publicado: (2016)

Genetically adjusted PSA levels for prostate cancer screening
por: Kachuri, Linda, et al.
Publicado: (2023)

The effect of the frequency and duration of prostate specific antigen (PSA) measurement on PSA doubling time calculations in men with biochemically recurrent prostate cancer
por: Paller, CJ, et al.
Publicado: (2013)

Improving power in PSA response analyses of metastatic castration-resistant prostate cancer trials
por: Grayling, Michael J., et al.
Publicado: (2022)

Management of a localized prostatic adenocarcinoma despite the very high rate of PSA and the large tumor mass: Does PSA level indicate the stage of prostate cancer?
por: el Farhaoui, Hammou, et al.
Publicado: (2023)

The global cancer divide: Relationships between national healthcare resources and cancer outcomes in high-income vs. middle- and low-income countries
por: Batouli, Ali, et al.
Publicado: (2014)

Treatment of local–regional prostate cancer detected by PSA screening: benefits and harms according to prognostic factors
por: Wever, E M, et al.
Publicado: (2013)

Diagnostic utility of p501s (prostein) in comparison to prostate specific antigen (PSA) for the detection of metastatic prostatic adenocarcinoma
por: Yin, Ming, et al.
Publicado: (2007)

Prostate-Specific Antigen (PSA) Screening and New Biomarkers for Prostate Cancer (PCa)
por: Stephan, Carsten, et al.
Publicado: (2014)

Does normalizing PSA after successful treatment of chronic prostatitis with high PSA value exclude prostatic biopsy?
por: Azab, Sherif, et al.
Publicado: (2012)

Detection of prostate cancer with complexed PSA and complexed/total PSA ratio - is there any advantage?
por: Strittmatter, F, et al.
Publicado: (2011)

The Relationship between Prostate Biopsy Results and PSA and Free PSA Ratio Changes in Elevated Serum PSA Patients with and without Antibiotherapy
por: Duran, Mesut Berkan, et al.
Publicado: (2020)

A Comparative Performance Analysis of Total PSA, Percentage Free PSA, PSA Velocity, and PSA Density versus the Detection of Primary Circulating Prostate Cells in Predicting Initial Prostate Biopsy Findings in Chilean Men
por: Murray, Nigel P., et al.
Publicado: (2014)

A case of metastatic cancer with markedly elevated PSA level that was not detected by repeat prostate biopsy
por: Iwamura, Hiromichi, et al.
Publicado: (2014)

Modeled Early Longitudinal PSA Kinetics Prognostic Value in Rising PSA Prostate Cancer Patients after Local Therapy Treated with ADT +/− Docetaxel
por: Carrot, Aurore, et al.
Publicado: (2022)

A Comprehensive Review of Contemporary Role of Local Treatment of the Primary Tumor and/or the Metastases in Metastatic Prostate Cancer
por: Aoun, Fouad, et al.
Publicado: (2014)

Association of Polymorphisms in the Prostate-Specific Antigen (PSA) Gene Promoter with Serum PSA Level and PSA Changes after Dutasteride Treatment in Korean Men with Benign Prostatic Hypertrophy
por: Park, Sung Woon, et al.
Publicado: (2010)

MRI/PET Imaging in elevated PSA and localized prostate cancer: a narrative review
por: Regmi, Subodh K., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_03jfma66veoqfu2cfj3nrvj448